

## BIBLIOGRAFIA:

1. Du Toit, R. M. The transmission of blue-tongue and horse-sickness by Culicoides. *J Vet Sc Anim Ind* 19, 7–16 (1944).
2. MacLachlan, N. J., Drew, C. P., Darpel, K. E. & Worwa, G. The Pathology and Pathogenesis of Bluetongue. *J. Comp. Pathol.* 141, 1–16 (2009).
3. Rushton, J. & Lyons, N. Economic impact of Bluetongue: a review of the effects on production. *Vet. Ital.* 51, 401–406 (2015).
4. Alonso, C. et al. Inhibition of Orbivirus Replication by Aurintricarboxylic Acid. *Int. J. Mol. Sci.* 21, (2020).
5. Mohd Jaafar, F., Monsion, B., Belhouchet, M., Mertens, P. P. C. & Attoui, H. Inhibition of Orbivirus Replication by Fluvastatin and Identification of the Key Elements of the Mevalonate Pathway Involved. *Viruses* 13, 1437 (2021).
6. Andrew, M. et al. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. *Vet. Immunol. Immunopathol.* 47, 311–322 (1995).
7. Jeggo, M. H., Wardley, R. C. & Brownlie, J. Importance of ovine cytotoxic T cells in protection against bluetongue virus infection. *Prog. Clin. Biol. Res.* 178, 477–487 (1985).
8. Boyce, M., Celma, C. C. P. & Roy, P. Bluetongue virus non-structural protein 1 is a positive regulator of viral protein synthesis. *Virol. J.* 9, 178 (2012).
9. Owens, R. J., Limn, C. & Roy, P. Role of an arbovirus nonstructural protein in cellular pathogenesis and virus release. *J. Virol.* 78, 6649–6656 (2004).
10. Maan, S. et al. Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains. *Virology* 377, 308–318 (2008).
11. Roy, P. Use of baculovirus expression vectors: development of diagnostic reagents, vaccines and morphological counterparts of bluetongue virus. *FEMS Microbiol. Immunol.* 2, 223–234 (1990).
12. Marín-López, A. et al. CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR<sup>−/−</sup> Mice. *J. Virol.* 92, e00938-18, /jvi/92/16/e00938-18.atom (2018).
13. Jiménez-Cabello, L. et al. Viral Vector Vaccines against Bluetongue Virus. *Microorganisms* 9, (2020).
14. Calvo-Pinilla, E. et al. A protective bivalent vaccine against Rift Valley fever and bluetongue. *Npj Vaccines* 5, 1–12 (2020).
15. Calvo-Pinilla, E., Rodríguez-Calvo, T., Sevilla, N. & Ortego, J. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR<sup>−/−</sup> mice against lethal bluetongue infection. *Vaccine* 28, 437–445 (2009).
16. Toussaint, J. F., Sailleau, C., Breard, E., Zientara, S. & De Clercq, K. Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments. *J. Virol. Methods* 140, 115–123 (2007).
17. Utrilla-Trigo, S. et al. Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8<sup>+</sup> T Cell Immunity to Bluetongue Virus. *Vaccines* 8, 346 (2020).
18. Utrilla-Trigo, S. et al. The Combined Expression of the Non-structural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge. *J. Virol.* (2021) doi:10.1128/JVI.01614-21.



19. Anderson, J. et al. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle. *Vaccine* 32, 6614–6621 (2014).
20. Rojas, J.M.; Martín, V.; Sevilla, N. Vaccination as a Strategy to Prevent Bluetongue Virus Vertical Transmission. *Pathogens* 2021, 10, 1528. <https://doi.org/10.3390/pathogens10111528>

